NASDAQ: AMGN
Amgen is a biotechnology company that discovers, develops, manufactures and sells medicines in general medicine, rare disease, inflammation and oncology, and is building a position in obesity and obesity-related conditions. Key growth products include:
- Repatha (cholesterol lowering) and EVENITY (osteoporosis)
- Rare disease therapies acquired with Horizon and ChemoCentryx: TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS
- TEZSPIRE for severe asthma, co-developed with AstraZeneca
- Oncology medicines BLINCYTO, IMDELLTRA, Vectibix, KYPROLIS, LUMAKRAS and Nplate
Amgen also sells biosimilars, including AMJEVITA, PAVBLU, WEZLANA and MVASI, and established products Aranesp, Neulasta and Parsabiv. Older franchises are under pressure: Prolia and XGEVA from denosumab biosimilars, and Enbrel from IRA Medicare Part D price setting. Most product sales are generated in the U.S., with the rest from international markets. The late-stage pipeline includes MariTide (monthly or less-frequent GLP-1/GIPR antibody-peptide conjugate for obesity), olpasiran (Lp(a) siRNA), xaluritamig (prostate cancer), dazodalibep (Sjögren's disease) and several biosimilars of major oncology and immunology biologics. Amgen is a component of the Dow Jones Industrial Average and the Nasdaq-100. Updated
Amgen just cleared its October 30 record with a $478.48 close, 2.68% above the prior peak and the fourth new high in barely a week. Anyone waiting for a pullback in this biotech hasn't gotten one.
Biosimilars cut Prolia 45% and XGEVA 47%, yet Amgen still came in 11.55% above expectations. Management now guides full-year non-GAAP EPS of $22.90 to $23.70, the number to judge the denosumab cliff against.
The retiring Yum! Brands CEO brings three decades of global consumer scale and pricing discipline to a $242 billion drugmaker that is leaning hard on commercial execution behind obesity and oncology bets. Board additions rarely move a stock, but they signal where management wants outside pressure applied.
Amgen closed at $447.28, a new 52-week high, roughly 55% above last October's $288 level. The $241.8 billion name now sits at the top of its range.
One biotech pays retirees a bigger check today, while the other carries no net debt and is growing far faster. We put Amgen and Regeneron side by side on income, valuation, and…
Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.…
Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug price controls close in. One number shows whether the…
Chris Lange AMD just reported a quarter that sent shockwaves through premarket trading, but whether one blowout earnings report can rebuild confidence across the entire AI trade is a question the rest of the…
Mounjaro and Zepbound just handed Lilly a blowout quarter, but falling realized drug prices and one-time revenue boosts that won't repeat raise real questions about whether the rally holds from here.
Collecting four figures a month from dividends without ever selling a share sounds straightforward until you price out what it actually costs and see which companies are holding the whole structure together.
Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned…
Rich Duprey When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one…
Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades. The question…
A European regulatory endorsement for an oral obesity pill is lifting Eli Lilly (NYSE:LLY | LLY Price Prediction) stock ahead of the rest of the drug group. Eli Lilly stock is up…
Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that…
Retirees watching CD rates scrape bottom and Treasury coupons well below their recent peaks have a third option hiding in plain sight inside the Dow Jones Industrial Average, and it requires owning…
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something…
Every dividend dollar sitting in a taxable account quietly hands a portion of itself to the IRS year after year, and after two decades that quiet cost compounds into a number most…
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
Amgen is a biotechnology company that discovers, develops, manufactures and sells medicines in general medicine, rare disease, inflammation and oncology, and is building a position in obesity and obesity-related conditions.
24/7 Wall St.'s 12-month price target for AMGN is $521.57, rated Buy. The Wall Street consensus target is $429.74. AMGN price prediction →
